How research on human progeroid and antigeroid syndromes can contribute to the longevity dividend initiative

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 4, 2016, Pages

  Hisama, Fuki M ^a   Oshima, Junko ^a,b   Martin, George M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOGEN; RECQ HELICASE;

AGE RELATED MACULAR DEGENERATION; AGING; AICARDI GOUTIERES SYNDROME; ALLELE; ALZHEIMER DISEASE; ANTIGEROID SYNDROME; ARTICLE; ATAXIA TELANGIECTASIA; ATHEROSCLEROSIS; BLOOM SYNDROME; COCKAYNE SYNDROME; CONGENITAL GENERALIZED LIPODYSTROPHY; FAMILIAL COLON POLYPOSIS; FANCONI ANEMIA; GENETIC DISORDER; GENETIC RESISTANCE; HEARING IMPAIRMENT; HUMAN; LAMINOPATHY; LONGEVITY; MANDIBLE HYPOPLASIA; MDPL SYNDROME; MOSAICISM; MYOTONIC DYSTROPHY; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PROGERIA; PROGEROID SYNDROME; ROTHMUND THOMSON SYNDROME; RUIJS AALFS SYNDROME; SOMATIC CELL GENETICS; SYNDROME; TRISOMY 8; WERNER SYNDROME; XERODERMA PIGMENTOSUM; GENETICS; GENOMIC INSTABILITY; MEDICAL RESEARCH; MULTIPLE MALFORMATION SYNDROME;

ABNORMALITIES, MULTIPLE; AGING; ALZHEIMER DISEASE; BIOMEDICAL RESEARCH; GENETIC DISEASES, INBORN; GENOMIC INSTABILITY; HUMANS; LONGEVITY; SYNDROME; WERNER SYNDROME;

EID: 84962406636     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025882     Document Type: Article

References (169)

1. Agrawala RK, Choudhury AK, Mohanty BK, Baliarsinha AK. 2014. Berardinelli-Seip congenital lipodystrophy: An autosomal recessive disorder with rare association of duodenocolonic polyps. J Pediatr Endocrinol Metab 27: 989-991.
2. Anderson JL, Ashwell CM, Smith SC, Shine R, Smith EC, Taylor RL Jr. 2013. Atherosclerosis-susceptible and atherosclerosis-resistant pigeon aortic cells express different genes in vivo. Poult Sci 92: 2668-2680.
3. Andres V, Gonzalez JM. 2009. Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol 187: 945-957.
4. Auerbach AD. 2009. Fanconi anemia and its diagnosis. Mu-tatRes 668: 4-10.
5. Awan Z, Baass A, Genest J. 2014. Proprotein convertase sub-tilisin/kexin type 9 (PCSK9): Lessons learned from patients with hypercholesterolemia. Clin Chem 60: 1380-1389.
6. Axford MM, Pearson CE. 2013. Illuminating CNS and cognitive issues in myotonic dystrophy: Workshop report. Neuromuscul Disord 23: 370-374.
7. Bachinski LL, Baggerly KA, Neubauer VL, Nixon TJ, Ra-heem O, Sirito M, Unruh AK, Zhang J, Nagarajan L, Timchenko LT, et al. 2014. Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies. Neu-romuscul Disord 24: 227-240.
8. Baidas S, Chen TJ, Kolev V, Wong LJ, Imholte J, Qin N, Meck J. 2004. Constitutional trisomy 8 mosaicism due to mei-osis II non-disjunction in a phenotypically normal woman with hematologic abnormalities. Am J Med Genet A 124A: 383-387.
9. Ben-Gedalya T, Cohen E. 2012. Quality control compartments coming of age. Traffic 13: 635-642.
10. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, et al. 2014. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord 29: 454-462.
11. Bernhard D, Moser C, Backovic A, Wick G. 2007. Cigarette smoke—An aging accelerator? Exp Gerontol 42:160-165.
12. Bjorkegren JL, Kovacic JC, Dudley JT, Schadt EE. 2015. Genome-wide significant loci: How important are they?: Systems genetics to understand heritability of coronary artery disease and other common complex disorders. J Am Col Cardiol 65: 830-845.
13. Blank A, Bobola MS, Gold B, Varadarajan S, Kolstoe DD, Meade EH, Rabinovitch PS, Loeb LA, Silber JR. 2004. The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: Implications for WRN function. DNA Repair (Amst) 3: 629-638.
14. Bloom D. 1954. Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs; probably a syndrome entity. AMA Am JDis Child 88: 754-758.
15. Brody JP. 2009. Parallel routes of human carcinoma development: Implications of the age-specific incidence data. PLoS ONE 4: e7053.
16. Capell BC, Collins FS. 2006. Human laminopathies: Nuclei gone genetically awry. Nat Rev Genet 7: 940-952.
17. Centore RC, Yazinski SA, Tse A, Zou L. 2012. Spartan/ C1orf124, a reader of PCNA ubiquitylation and a regu-lator of UV-induced DNA damage response. Mol Cell 46: 625-635.
18. Chaganti RS, Schonberg S, German J. 1974. A manyfold increase in sister chromatid exchanges in Bloom's syndrome lymphocytes. Proc Natl Acad Sci 71: 4508-4512.
19. Chang E, Harley CB. 1995. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci 92: 11190-11194.
20. Chatre L, Biard DS, Sarasin A, Ricchetti M. 2015. Reversal of mitochondrial defects with CSB-dependent serine protease inhibitors in patient cells ofthe progeroid Cockayne syndrome. Proc Natl Acad Sci 112: E2910-2919.
21. Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, Botha EG, Garg A, Hanson NB, Martin GM, et al. 2003. LMNA mutations in atypical Werner's syndrome. Lancet 362: 440-445.
22. Chen Y, Neve R, Zheng H, Griffin W, Barger S, Mrak R. 2014. Cycle on Wheels: Is APP key to the AppBp1 pathway? Austin Alzheimers Parkinsons Dis 1: id1008.
23. Cheung HH, Liu X, Canterel-Thouennon L, Li L, Edmon-son C, Rennert OM. 2014. Telomerase protects Werner syndrome lineage-specific stem cells from premature aging. Stem Cell Rep 2: 534-546.
24. Chouraki V, Seshadri S. 2014. Genetics of Alzheimer's disease. Adv Genet 87: 245-294.
25. Clark GR, Duncan EL. 2015. The genetics of osteoporosis. BrMedBull 113: 73-81.
26. Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, Colopy GW, Dreau H, Sigaux F, Judde JG, et al. 2013. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood 123: 1021-1031.
27. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923.
28. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. 1994. Protective effect ofapolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7: 180-184.
29. Corder EH, Basun H, Fratiglioni L, Guo Z, Lannfelt L, Vii-tanen M, Corder LS, Manton KG, Winblad B. 2000. Inherited frailty. ApoE alleles determine survival after a diagnosis of heart disease or stroke at ages 85+. Ann NY Acad Sci 908: 295-298.
30. Croteau DL, Popuri V, Opresko PL, Bohr VA. 2014. Human RecQ helicases in DNA repair, recombination, and replication. Annu Rev Biochem 83: 519-552.
31. Dale RC, Gornall H, Singh-Grewal D, Alcausin M, Rice GI, Crow YJ. 2010. Familial Aicardi -Goutieres syndrome due to SAMHD1 mutations is associated with chronic arthropathy and contractures. Am J Med Genet A 152A: 938-942.
32. De S, Kumari J, Mudgal R, Modi P, Gupta S, Futami K, Goto H, Lindor NM, Furuichi Y, Mohanty D, et al. 2012. RECQL4 is essential for the transport of p53 to mitochondria in normal human cells in the absence of exogenous stress. JCell Sci 125: 2509-2522.
33. DiGiovanna JJ, Kraemer KH. 2012. Shining a light on xeroderma pigmentosum. J invest dermatol 132: 785-796.
34. Dragani TA, Canzian F, Pierotti MA. 1996. A polygenic model of inherited predisposition to cancer. FASEB J 10: 865-870.
35. Drenos F, Kirkwood TB. 2010. Selection on alleles affecting human longevity and late-life disease: The example of apolipoprotein E. PLoS ONE 5: e10022.
36. Drouin CA, Mongrain E, Sasseville D, Bouchard HL, Drouin M. 1993. Rothmund-Thomson syndromewith osteosarcoma. J Am Acad Dermatol 28: 301-305.
37. Durno CA, Sherman PM, Aronson M, Malkin D, Hawkins C, Bakry D, Bouffet E, Gallinger S, Pollett A, Campbell B, et al. 2015. Phenotypic and genotypic characterisation of biallelic mismatch repair deficiency (BMMR-D) syndrome. Eur J Cancer 51: 977-983.
38. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, et al. 2003. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423: 293-298.
39. Esplin ED, Oei L, Snyder MP. 2014. Personalized sequencing and the future of medicine: Discovery, diagnosis and defeat of disease. Pharmacogenomics 15: 1771-1790.
40. Fan L, DuPrez KT. 2015. XPB: An unconventional SF2 DNA helicase. Prog Biophys Mol Biol 117: 174-181.
41. Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. 2005. LRRK2 mutations in Parkinson disease. Neurology 65: 738-740.
42. Finch C, Kirkwood TBL. 2000. Chance, development, and aging. Oxford University Press, New York.
43. Fineman RM, Ablow RC, Howard RO, Albright J, Breg WR. 1975. Trisomy 8 mosaicism syndrome. Pediatrics 56: 762-767.
44. Fishbein GA, Fishbein MC. 2009. Arteriosclerosis: Rethinking the current classification. Arch Pathol Lab Med 133: 1309-1316.
45. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, Panourgia MP, Invidia L, Celani L, Scurti M, et al. 2007. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 128: 92-105.
46. Friedrich K, Lee L, Leistritz DF, Nurnberg G, Saha B, Hisama FM, Eyman DK, Lessel D, Nurnberg P, Li C, et al. 2010. WRN mutations inWerner syndrome patients: Genomic rearrangements, unusual intronic mutations and ethnicspecific alterations. Hum Genet 128: 103-111.
47. Fritsche LG, Fariss RN, Stambolian D, Abecasis GR, Curcio CA, Swaroop A. 2014. Age-related macular degeneration: Genetics and biology coming together. Annu Rev Genomics Hum Genet 15: 151-171.
48. Fujioka H, Phelix CF, Friedland RP, Zhu X, Perry EA, Castellani RJ, Perry G. 2013. Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: Implications for differences in racial susceptibility to Alzheimer’s disease. J Health Care Poor Underserved 24: 70-78.
49. Galvan A, Falvella FS, Spinola M, Frullanti E, Leoni VP, Noci S, Alonso MR, Zolin A, Spada E, Milani S, et al. 2008. A polygenic model with commonvariants may predict lung adenocarcinoma risk in humans. Int J Can 123: 2327-2330.
50. Gao J, Liu RT, Cao S, Cui JZ, Wang A, To E, Matsubara JA. 2015. NLRP3 inflammasome: Activation and regulation in age-related macular degeneration. Mediators Inflamm 2015: 690243.
51. German J, Bloom D, Passarge E. 1984. Bloom’s syndrome XI. Progress report for 1983. Clin Genet 25: 166-174.
52. Goldstein JL, Dana SE, Brunschede GY, Brown MS. 1975. Genetic heterogeneity in familial hypercholesterolemia: Evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci 72: 1092-1096.
53. Gordon LB, Brown WT, Collins FS. 1993. Hutchinson-Gilford progeria syndrome. GeneReviews, University of Washington, Seattle.
54. Gordon LB, Massaro J, D’Agostino RB Sr, Campbell SE, Brazier J, Brown WT, Kleinman ME, Kieran MW, Progeria Clinical Trials C. 2014. Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 130: 27-34.
55. Goto M, Miller RW, Ishikawa Y, Sugano H. 1996. Excess of rare cancers inWerner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5: 239-246.
56. Grein Cavalcanti L, Fatima Lyko K, Lins Fuentes Araujo R, Miguel Amenabar J, Bonfim C, Carvalho Torres-Pereira C. 2015. Oral leukoplakia in patients with Fanconi anaemiawithout hematopoietic stem cell transplantation. Pediatr Blood Cancer 62: 1024-1026.
57. Gupta S, De S, Srivastava V, Hussain M, Kumari J, Muniyappa K, Sengupta S. 2014. RECQL4 and p53 potentiate the activity of polymerase g and maintain the integrity of the human mitochondrial genome. Carcinogenesis 35: 34-45.
58. Harper PS, Brook JD, Newman E. 2001.Myotonic dystrophy. WB Saunders, New York.
59. Hisama FM, Lessel D, Leistritz D, Friedrich K, McBride KL, Pastore MT, Gottesman GS, Saha B, Martin GM, Kubisch C, et al. 2011. Coronary artery disease in a Werner syndrome- like form of progeria characterized by lowlevels of progerin, a splice variant of lamin A. Am J Med Genet A 155A: 3002-3006.
60. Hoki Y, Araki R, Fujimori A, Ohhata T, Koseki H, Fukumura R, Nakamura M, Takahashi H, Noda Y, Kito S, et al. 2003. Growth retardation and skin abnormalities of the Recql4-deficient mouse. Hum Mol Genet 12: 2293-2299.
61. Ibrahim A, Barnes DR, Dunlop J, Barrowdale D, Antoniou AC, Berg JN. 2014. Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. Eur J Hum Genet 22: 1330-1333.
62. Jaarsma D, van der Pluijm I, van der Horst GT, Hoeijmakers JH. 2013. Cockayne syndrome pathogenesis: Lessons from mouse models. Mech Ageing Dev 134: 180-195.
63. Jasperson KW. 2012. Genetic testing by cancer site: Colon (polyposis syndromes). Cancer J 18: 328-333.
64. Jeninga EH, de Vroede M, Hamers N, Breur JM, Verhoeven-Duif NM, Berger R, Kalkhoven E. 2012. A patient with congenital generalized lipodystrophy due to a novel mutation in BSCL2: Indications for secondary mitochondrial dysfunction. JIMD Reps 4: 47-54.
65. Jeppesen DK, Bohr VA, Stevnsner T. 2011. DNA repair deficiency in neurodegeneration. Prog Neurobiol 94: 166-200.
66. Kamath-Loeb AS, Shen JC, Schmitt MW, Loeb LA. 2012. The Werner syndrome exonuclease facilitates DNA degradation and high fidelity DNA polymerization by human DNA polymerase d. J Biol Chem 287: 12480-12490.
67. Kaneko H, Kondo N. 2004. Clinical features of Bloom syndrome and function of the causative gene, BLM helicase. Expert Rev Mol Diagn 4: 393-401.
68. Karass M, Naguib MM, Elawabdeh N, Cundiff CA, Thomason J, Steelman CK, Cone R, Schwenkter A, Jordan C, Shehata BM. 2014. Xeroderma pigmentosa: Three new cases with an in depth review of the genetic and clinical characteristics of the disease. Fetal Pediatr Pathol 34: 120-127.
69. Kim J, Yoon H, Basak J, Kim J. 2014. Apolipoprotein E in synaptic plasticity and Alzheimer’s disease: Potential cellular and molecular mechanisms. Mol Cells 37: 767-776.
70. Kitao S, Shimamoto A, Goto M, Miller RW, Smithson WA, Lindor NM, Furuichi Y. 1999. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet 22: 82-84.
71. Klein C, Schlossmacher MG. 2006. The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2: 136-146.
72. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, San Giovanni JP, Mane SM, Mayne ST, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
73. Kwan P. 2015. Osteoporosis: From osteoscience to neuroscience and beyond. Mech Ageing Dev 145C: 26-38.
74. Laberge L, Gagnon C, Dauvilliers Y. 2013. Daytime sleepiness and myotonic dystrophy. Curr Neurol Neurosci Rep 13: 340.
75. Larson EB, Kukull WA, Katzman RL. 1992. Cognitive impairment: Dementia and Alzheimer’s disease. Annu Rev Public Health 13: 431-449.
76. Laugel V. 2013. Cockayne syndrome: The expanding clinical and mutational spectrum. Mech Ageing Dev 134: 161-170.
77. Lawson MA. 2009. Lipoatrophic diabetes: Acase report with a brief reviewof the literature. J Adolesc Health 44: 94-95.
78. Lessel D, Saha B, Hisama F, Kaymakamzade B, Nurlu G, Gursoy-Ozdemir Y, Thiele H, Nurnberg P, Martin GM, Kubisch C, et al. 2014a. Atypical Aicardi-Goutieres syndrome: is the WRN locus a modifier? Am J Med Genet A 164A: 2510-2513.
79. Lessel D, Vaz B, Halder S, Lockhart PJ, Marinovic-Terzic I, Lopez-Mosqueda J, Philipp M, Sim JC, Smith KR, Oehler J, et al. 2014b. Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet 46: 1239-1244.
80. Li X, Schulte P, Godin DV, Cheng KM. 2012. Differential mRNA expression of seven genes involved in cholesterol metabolism and transport in the liver of atherosclerosissusceptible and -resistant Japanese quail strains. Genet Sel Evol 44: 20.
81. Liebetrau W, Runge TM, Baumer A, Henning C, Gross O, Schindler D, Poot M, Hoehn H. 1997. Exploring the role of oxygen in Fanconi’s anemia. Recent Results Cancer Res 143: 353-367.
82. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, Huang JD, Li KM, Chau PY, Chen DJ, et al. 2005. Genomic instability in laminopathy-based premature aging. Nat Med 11: 780-785.
83. Liu Y, Rusinol A, Sinensky M, Wang Y, Zou Y. 2006. DNA damage responses in progeroid syndromes arise from defective maturation of prelamin A. J Cell Sci 119: 4644-4649.
84. Lord J, Lu AJ, Cruchaga C. 2014. Identification of rare variants in Alzheimer’s disease. Front Genet 5: 369.
85. Machado PV, Daxbacher EL, Obadia DL, Cunha EF, Alves Mde F, Mann D. 2013. Do you know this syndrome? Berardinelli-Seip syndrome. An Bras Dermatol 88: 1011-1013.
86. Machwe A, Karale R, Xu X, Liu Y, Orren DK. 2011. The Werner and Bloom syndrome proteins help resolve replication blockage by converting (regressed) Holliday junctions to functional replication forks. Biochemistry 50: 6774-6788.
87. Malatesta M, Cardani R, Pellicciari C, Meola G. 2014. RNA transcription and maturation in skeletal muscle cells are similarly impaired in myotonic dystrophy and sarcopenia: The ultrastructural evidence. Front Aging Neurosci 6: 196.
88. Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JH. 2014. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol 15: 465-481.
89. Martin GM. 1978. Genetic syndromes in manwith potential relevance to the pathobiology of aging. Birth Defects Orig Art Ser 14: 5-39.
90. Martin GM. 1982. Syndromes of accelerated aging. Natl Cancer Inst Monogr 60: 241-247.
91. Martin GM. 1987. Interactions of aging and environmental agents: The gerontological perspective. Prog Clin Biol Res 228: 25-80.
92. Martin GM. 1998. Atherosclerosis is the leading cause of death in the developed societies. Am J Pathol 153: 1319-1320.
93. Martin GM. 1999. APOE alleles and lipophylic pathogens. Neurobiol Aging 20: 441-443.
94. Martin GM. 2002. Help wanted: Physiologists for research on aging. Sci Aging Knowledge Environ 2002: vp2.
95. Martin GM. 2005. Genetic modulation of senescent phenotypes in Homo sapiens. Cell 120: 523-532.
96. Martin GM. 2009. Epigenetic gambling and epigenetic drift as an antagonistic pleiotropic mechanism of aging. Aging Cell 8: 761-764.
97. Martin GM. 2012. Stochastic modulations of the pace and patterns of ageing: Impacts on quasi-stochastic distributions of multiple geriatric pathologies. Mech Ageing Dev 133: 107-111.
98. Martin GM, Oshima J. 2000. Lessons from human progeroid syndromes. Nature 408: 263-266.
99. Martin GM, Sprague CA. 1972. Clonal senescence and atherosclerosis. Lancet 2: 1370-1371.
100. Martin GM, Sprague CA. 1973. Symposium on in vitro studies related to atherogenesis. Life histories of hyperplastoid cell lines from aorta and skin. ExpMol Pathol 18: 125-141.
101. Martin GM, Ogburn CE, Wight TN. 1983. Comparative rates of decline in the primary cloning efficiencies of smooth muscle cells from the aging thoracic aorta of two murine species of contrasting maximum life span potentials. Am J Pathol 110: 236-245.
102. McClintock D, Ratner D, Lokuge M, Owens DM, Gordon LB, Collins FS, Djabali K. 2007. The mutant form of lamin A that causes Hutchinson-Gilford progeria is a biomarker of cellular aging in human skin. PLoS ONE 2: e1269.
103. McIntosh AM, Bennett C, Dickson D, Anestis SF, Watts DP, Webster TH, Fontenot MB, Bradley BJ. 2012. The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes). PLoS ONE 7: e47760.
104. Medawar P. 1952. An unsolved problem in biology. H.K. Lewis, London.
105. Meola G, Cardani R. 2015.Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Biochim Biophys Acta 1852: 594-606.
106. Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, et al. 2008. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med 358: 592-604.
107. Meyer JN, Leung MC, Rooney JP, Sendoel A, Hengartner MO, Kisby GE, Bess AS. 2013. Mitochondria as a target of environmental toxicants. Toxicol Sci 134: 1-17.
108. Meyn MS. 1993. High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia. Science 260: 1327-1330.
109. _ Milman S, Barzilai N. 2015. Dissecting the mechanisms underlying unusually successful human healthspan and lifespan. Cold Spring Harb Persect Med doi: 10.1101/cshperspect.a025098.
110. Miyake Y, Tanaka K, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, et al. 2012. UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan. BMC Neurol 12: 62.
111. Morimoto RI, Cuervo AM. 2014. Proteostasis and the aging proteome in health and disease. J Gerontol A Biol Sci Med Sci 69 (Suppl. 1): S33-S38.
112. Nayak S, Edwards DL, Saleh AA, Greenspan SL. 2015. Systematic review and meta-analysis of the performance of clinical risk assessment instruments for screening for osteoporosis or low bone density. Osteoporos Int 26: 1543-1554.
113. Nelson MD, Victor RG, Szczepaniak EW, Simha V, Garg A, Szczepaniak LS. 2013. Cardiac steatosis and left ventricular hypertrophy in patients with generalized lipodystrophy as determined by magnetic resonance spectroscopy and imaging. Am J Cardiol 112: 1019-1024.
114. Neveling K, Endt D, Hoehn H, Schindler D. 2009. Genotype-phenotype correlations in Fanconi anemia. Mutat Res-Fund Mol M 668: 73-91.
115. Nhan HS, Chiang K, Koo EH. 2015. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol 129: 1-19.
116. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, et al. 2009.Mutations in GBAare associated with familial Parkinson disease susceptibility and age at onset. Neurology 72: 310-316.
117. Nisbet RM, Polanco JC, Ittner LM, Gotz J. 2015. Tau aggregation and its interplay with amyloid-b. Acta Neuropathol 129: 207-220.
118. Nolis T. 2014. Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. J Hum Genet 59: 16-23.
119. Ogburn CE, Oshima J, Poot M, Chen R, Hunt KE, Gollahon KA, Rabinovitch PS, Martin GM. 1997. An apoptosisinducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet 101: 121-125.
120. O’Gorman W, Thomas B, Kwek KY, Furger A, Akoulitchev A. 2005. Analysis of U1 small nuclear RNA interaction with cyclin H. J Biol Chem 280: 36920-36925.
121. Okuda K, Khan MY, Skurnick J, Kimura M, Aviv H, Aviv A. 2000. Telomere attrition of the human abdominal aorta: relationships with age and atherosclerosis. Atherosclerosis 152: 391-398.
122. Olive M, Harten I, Mitchell R, Beers JK, Djabali K, Cao K, Erdos MR, Blair C, Funke B, Smoot L, et al. 2010. Cardiovascular pathology in Hutchinson-Gilford progeria: Correlation with the vascular pathology of aging. Arterioscler Thromb Vasc Biol 30: 2301-2309.
123. Oostra AB, Nieuwint AW, Joenje H, de Winter JP. 2012. Diagnosis of Fanconi anemia: Chromosomal breakage analysis. Anemia 2012: 238-731.
124. Oshima J, Hisama FM. 2014. Search and insights into novel genetic alterations leading to classical and atypical Werner syndrome. Gerontology 60: 239-246.
125. Oshima J, Martin GM, Hisama FM. 2014. Werner syndrome. In GeneReviews(R) (ed. Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K). University of Washington, Seattle, WA.
126. Ow SY, Dunstan DE. 2014. A brief overview of amyloids and Alzheimer’s disease. Protein Sci 23: 1315-1331.
127. Pagano G, Shyamsunder P, Verma RS, Lyakhovich A. 2014. Damaged mitochondria in Fanconi anemia—An isolated event or a general phenomenon? Oncoscience 1: 287-295.
128. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, et al. 2013. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45: 136-144.
129. Pelosini C, Martinelli S, Ceccarini G, Magno S, Barone I, Basolo A, Fierabracci P, Vitti P, Maffei M, Santini F. 2014. Identification of a novel mutation in the polymerase delta 1 (POLD1) gene in a lipodystrophic patient affected by mandibular hypoplasia, deafness, progeroid features (MDPL) syndrome. Metabolism 63: 1385-1389.
130. Phillips MC. 2014. Apolipoprotein E isoforms and lipoprotein metabolism. IUBMB Life 66: 616-623.
131. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE. 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78: 959-991.
132. Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pges MP, Vasquez N, d’Enghien CD, Larghero J, de Latour RP, et al. 2011.Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood 117: E161-E170.
133. Rajpathak SN, Liu Y, Ben-David O, Reddy S, Atzmon G, Crandall J, Barzilai N. 2011. Lifestyle factors of people with exceptional longevity. J Am Geriatr Soc 59: 1509-1512.
134. Rao CV, Yamada HY. 2013. Genomic instability and colon carcinogenesis: From the perspective of genes. Front Oncol 3: 130.
135. Ratnapriya R, Chew EY. 2013. Age-related macular degeneration—Clinical review and genetics update. Clin Genet 84: 160-166.
136. Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, Fuller JC, Jackson RM, Lamb T, Briggs TA, et al. 2009. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet 41: 829-832.
137. Roberts R. 2015. A genetic basis for coronary artery disease. Trends Cardiovasc Med 25: 171-178.
138. Ruijs MW, van Andel RN, Oshima J, Madan K, Nieuwint AW, Aalfs CM. 2003. Atypical progeroid syndrome: An unknown helicase gene defect? Am J Med Genet A 116A: 295-299.
139. Saha B, Cypro A, Martin GM, Oshima J. 2014. Rapamycin decreases DNA damage accumulation and enhances cell growth of WRN-deficient human fibroblasts. Aging Cell 13: 573-575.
140. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, et al. 1995. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268: 1749-1753.
141. Schottker B, Saum KU, Jansen EH, Boffetta P, Trichopoulou A, Holleczek B, Dieffenbach AK, Brenner H. 2015. Oxidative stress markers and all-cause mortality at older age: A population-based cohort study. J Gerontol A Biol Sci Med Sci 70: 518-524.
142. Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW, Melista E, Andersen S, Dworkis DA, Wilk JB, et al. 2012. Genetic signatures of exceptional longevity in humans. PLoS ONE 7: e29848.
143. Shalev SA, De Sandre-Giovannoli A, Shani AA, Levy N. 2007. An association of Hutchinson-Gilford progeria and malignancy. Am J Med Genet A 143A: 1821-1826.
144. Shimamoto A, Kagawa H, Zensho K, Sera Y, Kazuki Y, Osaki M, Oshimura M, Ishigaki Y, Hamasaki K, Kodama Y, et al. 2014. Reprogramming suppresses premature senescence phenotypes of Werner syndrome cells and maintains chromosomal stability over long-term culture. PLoS ONE 9: e112900.
145. Siitonen HA, Kopra O, Kaariainen H, Haravuori H, Winter RM, Saamanen AM, Peltonen L, Kestila M. 2003.Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases. Hum Mol Genet 12: 2837-2844.
146. Sobenin IA, Zhelankin AV, Sinyov VV, Bobryshev YV, Orekhov AN. 2014. Mitochondrial aging: Focus on mitochondrial DNA damage in atherosclerosis—A mini-review. Gerontology 61: 343-349.
147. Stephenson JB. 2008. Aicardi-Goutieres syndrome (AGS). Eur J Paediatr Neurol 12: 355-358.
148. Suri S, Heise V, Trachtenberg AJ, Mackay CE. 2013. The forgotten APOE allele: A review of the evidence and suggested mechanisms for the protective effect of APOE varepsilon2. Neurosci Biobehav Rev 37: 2878-2886.
149. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, et al. 1997. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386: 292-296.
150. Takemoto M, Yamaga M, Furuichi Y, Yokote K. 2015. Astaxantin improved non-alcoholic fatty liver disease in Werner syndrome with diabetes. J Am Geristr Soc 63: 1271-1273.
151. Talaei F, van Praag VM, Henning RH. 2013.Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway. Pharmacol Res 74: 34-44.
152. Tang Y, Le W. 2015. Differential Roles of M1 and M2 Microglia in neurodegenerative diseases. Mol Neurobiol doi: 10.1007/s12035-014-9070-5.
153. Thomas GS, Wann LS, Allam AH, Thompson RC, Michalik DE, Sutherland ML, Sutherland JD, Lombardi GP, Watson L, Cox SL, et al. 2014. Why did ancient people have atherosclerosis?: From autopsies to computed tomography to potential causes. Global Heart 9: 229-237.
154. Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. 2005. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97: 813-822.
155. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, Navarro M, Segui N, Vargas G, Guarinos C, et al. 2014.New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 23: 3506-3512.
156. VanMaldergem L, Siitonen HA, Jalkh N, Chouery E, De Roy M, Delague V, Muenke M, Jabs EW, Cai J, Wang LL, et al. 2006. Revisiting the craniosynostosis-radial ray hypoplasia association: Baller-Gerold syndrome caused by mutations in the RECQL4 gene. J Med Genet 43: 148-152.
157. Vennos EM, James WD. 1995. Rothmund-Thomson syndrome. Dermatol Clin 13: 143-150.
158. Walden H, Deans AJ. 2014. The Fanconi anemiaDNA repair pathway: Structural and functional insights into a complex disorder. Annu Rev Biophys 43: 257-278.
159. Wang JC, Bennett M. 2012. Aging and atherosclerosis: Mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111: 245-259.
160. Wang LL, Levy ML, Lewis RA, Chintagumpala MM, Lev D, Rogers M, Plon SE. 2001. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 102: 11-17.
161. Wang M, Jiang L, Monticone RE, Lakatta EG. 2014. Proinflammation: The key to arterial aging. Trends Endocrinol Metab 25: 72-79.
162. Weedon MN, Ellard S, Prindle MJ, Caswell R, Lango Allen H, Oram R, Godbole K, Yajnik CS, Sbraccia P, Novelli G, et al. 2013. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nat Genet 45: 947-950.
163. Wei S, Soh SL, Qiu W, Yang W, Seah CJ, Guo J, Ong WY, Pang ZP, Han W. 2013. Seipin regulates excitatory synaptic transmission in cortical neurons. J Neurochem 124: 478-489.
164. Wilhelmsen L, Dellborg M, Welin L, Svardsudd K. 2015. Men born in 1913 followed to age 100 years. Scand Cardiovasc J 49: 45-48.
165. Williams GC. 1957. Pleiotropy, natural selection, and the evolution of senescence. Evolution 11: 3982411.
166. Willingale-Theune J, Schweiger M, Hirsch-Kauffmann M, Meek AE, Paulin-Levasseur M, Traub P. 1989. Ultrastructure of Fanconi anemia fibroblasts. J Cell Sci 93: 651-665.
167. Woods CG, Taylor AM. 1992. Ataxia telangiectasia in the British Isles: The clinical and laboratory features of 70 affected individuals. Q J Med 82: 169-179.
168. Wu L, Davies SL, Levitt NC, Hickson ID. 2001. Potential role for the BLM helicase in recombinational repair via a conserved interaction with RAD51. J Biol Chem 276: 19375-19381.
169. Xie Z, Jay KA, Smith DL, Zhang Y, Liu Z, Zheng J, Tian R, Li H, Blackburn EH. 2015. Early telomerase inactivation accelerates aging independently of telomere length. Cell 160: 928-939.